Article de Périodique
Cognitive-behavioral therapies in the management of adolescents with cannabis use disorder (CUD): A systematic review (2024)
Auteur(s) :
MAURIES, S. ;
DUFAYET, G. ;
LENGEREAU, A. ;
LEJOYEUX, M. ;
GEOFFROY, P. A. ;
DUPONG, I.
Année
2024
Page(s) :
art. 111321
Sous-type de document :
Revue de la littérature / Literature review
Langue(s) :
Anglais
Domaine :
Drogues illicites / Illicit drugs
Thésaurus mots-clés
CANNABIS
;
ADOLESCENT
;
THERAPIE COGNITIVO-COMPORTEMENTALE
;
PSYCHOTHERAPIE
;
PRISE EN CHARGE
;
EFFICACITE
;
TRAITEMENT
;
THERAPIE FAMILIALE
Résumé :
Introduction: Cannabis currently stands as the most prevalent illicit substance used by adolescents in France. Its use is associated with an elevated risk of developing psychiatric disorder, affecting neuro-cognitive development, or leading to psycho-social challenges in the long run. Cognitive-behavioral therapies (CBT) have emerged as a preferred approach for treating cannabis use disorders (CUD) in adults.
Methods: This review is grounded in a systematic search of the PubMed scientific database for randomized controlled trials focusing on CBT treatment for adolescents (12–18 years old) with CUD. Results Nine studies met the inclusion criteria. Currently, several variants of CBT-based treatments are available for adolescents, differing in duration based on the intended objectives (ranging from 3 to 24 weeks). These CBT therapies are often complemented by motivational interviewing or family therapy. Only two studies draw comparisons between CBT and alternative therapeutic approaches.
Discussion: The current scientific literature in this field is limited, and the study designs display heterogeneity. However, abbreviated treatment courses appear to have value, especially within the adolescent population. These courses offer treatment advantages and may enhance treatment adherence among these young patients, who may face challenges in maintaining consistent follow-up. Additionally, involving parents in psychotherapeutic care seems to have a positive impact.
Conclusion: CBT in adolescents with CUD appears to be a promising approach to assist with maintaining abstinence and managing emotions. However, given the diverse study designs found in the literature, conducting research with standardized treatments on larger patient cohorts would be valuable.
Methods: This review is grounded in a systematic search of the PubMed scientific database for randomized controlled trials focusing on CBT treatment for adolescents (12–18 years old) with CUD. Results Nine studies met the inclusion criteria. Currently, several variants of CBT-based treatments are available for adolescents, differing in duration based on the intended objectives (ranging from 3 to 24 weeks). These CBT therapies are often complemented by motivational interviewing or family therapy. Only two studies draw comparisons between CBT and alternative therapeutic approaches.
Discussion: The current scientific literature in this field is limited, and the study designs display heterogeneity. However, abbreviated treatment courses appear to have value, especially within the adolescent population. These courses offer treatment advantages and may enhance treatment adherence among these young patients, who may face challenges in maintaining consistent follow-up. Additionally, involving parents in psychotherapeutic care seems to have a positive impact.
Conclusion: CBT in adolescents with CUD appears to be a promising approach to assist with maintaining abstinence and managing emotions. However, given the diverse study designs found in the literature, conducting research with standardized treatments on larger patient cohorts would be valuable.
Affiliation :
Département de psychiatrie et d?addictologie, AP-HP, GHU Paris Nord, DMU Neurosciences, Hôpital Bichat - Claude Bernard, Paris, France
Inserm U1028, CNRS UMR5292, Université Claude Bernard Lyon 1, Bron, France
Université Paris Cité, NeuroDiderot, Inserm, FHU I2-D2, Paris, France
Centre ChronoS, GHU Paris - Psychiatry & Neurosciences, Paris, France
AP-HP, Child and Adolescent Psychopathology unit, Robert Debré Hospital, Paris, France
Inserm U1028, CNRS UMR5292, Université Claude Bernard Lyon 1, Bron, France
Université Paris Cité, NeuroDiderot, Inserm, FHU I2-D2, Paris, France
Centre ChronoS, GHU Paris - Psychiatry & Neurosciences, Paris, France
AP-HP, Child and Adolescent Psychopathology unit, Robert Debré Hospital, Paris, France
Historique